Clinical Trial Update: A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects [Phase 1]

View source ↗

Summary

This first-in-human Phase 1 trial assesses safety, tolerability, and pharmacokinetics of NNC0165-1562 after single and multiple dosing in overweight to obese bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• NNC0165-1562

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Metabolism and Nutrition Disorder, Obesity | Phase 1 | Status: COMPLETED